Cannabis Stocks Are Heating Up Again. Here's Which Ones Could be the Biggest Winners.

The DOJ/DEA rescheduling of marijuana from Schedule I to Schedule III is a major regulatory tailwind because it removes 280E restrictions, improving after-tax economics for cannabis operators. Trulieve reported Q1 revenue of $287 million and swung to $2.4 million in net income from a $32.9 million loss, while Curaleaf posted $324 million in revenue and $69.8 million in net income versus a $60.3 million loss a year earlier. Both stocks have risen more than 50% over the past three months, and the article argues that further federal hearings could extend benefits across the sector.

Analysis

The market is starting to price a regime shift, but the real edge is not in “rescheduling” itself — it’s in which operators have enough scale and balance-sheet flexibility to convert tax relief into durable incremental cash flow. The winners are the operators with dense footprints, existing profitability, and enough liquidity to fund inventory, capex, and potential M&A before less efficient peers can re-rate. That argues for a widening dispersion trade inside cannabis: large, vertically integrated MSOs should continue taking share from undercapitalized regional operators that cannot bridge the next 2-4 quarters without dilution.

The second-order effect is that tax reform matters more to equity holders than to the underlying demand curve. 280E relief should expand EBITDA margin first, but the larger medium-term catalyst is cost of capital compression: once the market believes earnings are structurally taxable at ordinary corporate rates rather than punitive levels, refinancing risk, asset sales, and uplisting probability all improve. That creates a feedback loop where better liquidity lowers spreads, which in turn makes these names more investable for institutions that currently cannot touch OTC liquidity or governance risk.

The main contrarian risk is that the market is extrapolating federal momentum faster than the legal process can deliver. If hearings slip or the scope narrows to medical-only for longer than expected, the trade can de-rate quickly because the current setup is predicated on forward tax normalization rather than current fundamentals alone. Near term, the more dangerous consensus assumption is that all operating leverage shows up immediately; in practice, cash tax refunds and amended returns are uncertain, while the market may already be discounting too much of 2025-2026 free cash flow improvement.

Relative value favors leaning into liquidity leaders and avoiding the weakest balance sheets. The better trade is not a broad sector basket, but a selective long in the most cash-generative MSOs against a short in smaller, higher-leverage peers that will lag on margin expansion and may still need equity capital even in a better tax regime.

Key Decisions for Investors

• Long CURLF vs. a basket of smaller MSOs for the next 3-6 months: Curaleaf has the better mix of international optionality and operating leverage to tax relief; target a relative re-rating as profitability becomes easier to underwrite.
• Initiate a tactical long TCNNF on pullbacks with a 2-4 month horizon: Trulieve’s dense Florida footprint gives it the highest incremental margin capture if adult-use legalization or broader tax relief materializes; use a tight stop if the policy timeline slips.
• Avoid chasing a broad cannabis ETF until hearing dates are resolved: the tape likely overprices the probability-weighted policy outcome; better risk/reward exists in single-name selection than in sector beta.
• Sell downside-protected puts on the strongest MSO names into volatility spikes over the next 1-2 months: implied vol should remain elevated into policy milestones, allowing premium capture while keeping entry levels disciplined.
• Pair trade long the profitable, liquid MSOs vs. short the most levered OTC operators over 3-6 months: the structural winner is capital access, and that advantage compounds if uplisting chatter gains credibility.